Xue Xia - Publications
Affiliations: | 2011-2015 | Biomedical Sciences | Florida State University, Tallahassee, FL, United States |
Year | Citation | Score | |||
---|---|---|---|---|---|
2016 | Xia X, Kumru OS, Blaber SI, Middaugh CR, Li L, Ornitz DM, Suh JM, Atkins AR, Downes M, Evans RM, Tenorio CA, Bienkiewicz E, Blaber M. An S116R Phosphorylation Site Mutation in Human Fibroblast Growth Factor-1 Differentially Affects Mitogenic and Glucose-Lowering Activities. Journal of Pharmaceutical Sciences. 105: 3507-3519. PMID 27773526 DOI: 10.1016/J.Xphs.2016.09.005 | 0.661 | |||
2016 | Xia X, Kumru OS, Blaber SI, Middaugh CR, Li L, Ornitz DM, Sutherland MA, Tenorio CA, Blaber M. Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for "Second Generation" Therapeutic Application. Journal of Pharmaceutical Sciences. 105: 1444-53. PMID 27019961 DOI: 10.1016/J.Xphs.2016.02.010 | 0.684 | |||
2016 | Xia X, Longo LM, Sutherland MA, Blaber M. Evolution of a protein folding nucleus. Protein Science : a Publication of the Protein Society. 25: 1227-40. PMID 26610273 DOI: 10.1002/Pro.2848 | 0.644 | |||
2015 | Xia X, Longo LM, Blaber M. Mutation choice to eliminate buried free cysteines in protein therapeutics. Journal of Pharmaceutical Sciences. 104: 566-76. PMID 25312595 DOI: 10.1002/Jps.24188 | 0.678 | |||
2012 | Xia X, Babcock JP, Blaber SI, Harper KM, Blaber M. Pharmacokinetic properties of 2nd-generation fibroblast growth factor-1 mutants for therapeutic application. Plos One. 7: e48210. PMID 23133616 DOI: 10.1371/Journal.Pone.0048210 | 0.61 | |||
2012 | Sipes RK, Xia X, Lewis BS, Burgis NE. Evidence that aberrant protein metabolism contributes to chemoresistance in multiple myeloma cells. Oncology Reports. 27: 2031-8. PMID 22426518 DOI: 10.3892/Or.2012.1716 | 0.3 | |||
Show low-probability matches. |